Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
EBIT MarginEBITDA MarginEBT MarginFCF MarginInterest Coverage RatioNet MarginOperating MarginReturn on SalesTimes Interest Earned

GT Biopharma (GTBP) Equity Ratio (2016 - 2021)

GT Biopharma (GTBP) has disclosed Equity Ratio for 12 consecutive years, with 0.89 as the latest value for Q3 2021.

  • On a quarterly basis, Equity Ratio rose 102.74% to 0.89 in Q3 2021 year-over-year; TTM through Sep 2021 was 0.89, a 102.74% increase, with the full-year FY2020 number at 5.2, up 89.34% from a year prior.
  • Equity Ratio was 0.89 for Q3 2021 at GT Biopharma, down from 0.92 in the prior quarter.
  • In the past five years, Equity Ratio ranged from a high of 21.2 in Q2 2019 to a low of 478.19 in Q2 2017.
  • A 5-year average of 35.12 and a median of 0.45 in 2018 define the central range for Equity Ratio.
  • Peak YoY movement for Equity Ratio: surged 2097.38% in 2019, then crashed 62706.39% in 2020.
  • GT Biopharma's Equity Ratio stood at 2.05 in 2017, then tumbled by 75.52% to 0.5 in 2018, then tumbled by 9819.56% to 48.76 in 2019, then surged by 89.34% to 5.2 in 2020, then surged by 117.13% to 0.89 in 2021.
  • Per Business Quant, the three most recent readings for GTBP's Equity Ratio are 0.89 (Q3 2021), 0.92 (Q2 2021), and 0.87 (Q1 2021).